We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Altimmune Inc | NASDAQ:ALT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.04 | 0.58% | 6.89 | 6.90 | 7.02 | 229 | 12:31:30 |
Details for the presentation are as follows:
Title: | Pemvidutide-induced liver fat reduction in subjects with non-alcoholic fatty liver disease correlate with improvements in non-invasive markers of inflammation and fibrosis: Results of a 24-week multicenter, randomized, double-blind, placebo-controlled trial |
Presenter: | Dr. Stephen Harrison, Medical Director, Pinnacle Research, and Adjunct Professor of Medicine, Oxford University |
Date/Time: | Late Breaking Poster Session, Monday, November 13, 2023, at 1:00 pm EST |
The late-breaking poster will be made available on the Events section of the Altimmune website at the time of the presentation.
About Pemvidutide Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, leading to rapid reductions in levels of liver fat. Pemvidutide incorporates the EuPort™ domain, a proprietary technology that increases its serum half-life for weekly dosing while likely slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability.
About AltimmuneAltimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Investor Contact:Richard EisenstadtChief Financial OfficerPhone: 240-654-1450reisenstadt@altimmune.com
Media Contact:Danielle CanteyEvoke CanalePhone: 619-826-4657danielle.cantey@evokegroup.com
1 Year Altimmune Chart |
1 Month Altimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions